# Novartis

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/novartis/

## Facts

| Field | Value |
| --- | --- |
| Country | CH |
| Description | Swiss-American multinational pharmaceutical corporation |
| OpenAlex ID | https://openalex.org/F4320307778 |
| ROR ID | https://ror.org/02f9zrr09 |
| Works | 11,880 |

## Funder papers

Showing 15 of 19.

- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function](https://scholariq.org/papers/safety-and-efficacy-of-eplerenone-in-patients-at-high-risk-for-hyperkalemia-and/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)
- [Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors](https://scholariq.org/papers/effect-of-patiromer-on-reducing-serum-potassium-and-preventing-recurrent/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease](https://scholariq.org/papers/efficacy-and-safety-of-spironolactone-in-patients-with-hfpef-and-chronic-kidney/)
- [Multifocal and Accommodating Intraocular Lenses for the Treatment of Presbyopia](https://scholariq.org/papers/multifocal-and-accommodating-intraocular-lenses-for-the-treatment-of-presbyopia/)
- [Analysis of Worsening Heart Failure Events in an Integrated Health Care System](https://scholariq.org/papers/analysis-of-worsening-heart-failure-events-in-an-integrated-health-care-system/)
- [Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors](https://scholariq.org/papers/genome-wide-profiling-of-non-smoking-related-lung-cancer-cells-reveals-common/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery](https://scholariq.org/papers/levosimendan-in-patients-with-reduced-left-ventricular-function-undergoing/)
- [Combined versus Sequential Phacoemulsification and Pars Plana Vitrectomy](https://scholariq.org/papers/combined-versus-sequential-phacoemulsification-and-pars-plana-vitrectomy/)
- [Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure](https://scholariq.org/papers/safety-and-efficacy-of-intravenous-ferric-derisomaltose-compared-to-iron-sucrose/)
- [Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis](https://scholariq.org/papers/spironolactone-in-patients-on-chronic-haemodialysis-at-high-risk-of-adverse/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.